DNA Methylation and Histone Modification in Low-Grade Gliomas: Current Understanding and Potential Clinical Targets.
ATRX
CpG island
DNMT
G-CIMP
H3K27M
MGMT
histone acetylation
methylation
methylomics
methyltransferases
tumor suppressor
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
20 Feb 2023
20 Feb 2023
Historique:
received:
21
12
2022
revised:
02
02
2023
accepted:
14
02
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
26
2
2023
Statut:
epublish
Résumé
Gliomas, the most common type of malignant primary brain tumor, were conventionally classified through WHO Grades I-IV (now 1-4), with low-grade gliomas being entities belonging to Grades 1 or 2. While the focus of the WHO Classification for Central Nervous System (CNS) tumors had historically been on histopathological attributes, the recently released fifth edition of the classification (WHO CNS5) characterizes brain tumors, including gliomas, using an integration of histological and molecular features, including their epigenetic changes such as histone methylation, DNA methylation, and histone acetylation, which are increasingly being used for the classification of low-grade gliomas. This review describes the current understanding of the role of DNA methylation, demethylation, and histone modification in pathogenesis, clinical behavior, and outcomes of brain tumors, in particular of low-grade gliomas. The review also highlights potential diagnostic and/or therapeutic targets in associated cellular biomolecules, structures, and processes. Targeting of MGMT promoter methylation, TET-hTDG-BER pathway, association of G-CIMP with key gene mutations, PARP inhibition, IDH and 2-HG-associated processes, TERT mutation and ARL9-associated pathways, DNA Methyltransferase (DNMT) inhibition, Histone Deacetylase (HDAC) inhibition, BET inhibition, CpG site DNA methylation signatures, along with others, present exciting avenues for translational research. This review also summarizes the current clinical trial landscape associated with the therapeutic utility of epigenetics in low-grade gliomas. Much of the evidence currently remains restricted to preclinical studies, warranting further investigation to demonstrate true clinical utility.
Identifiants
pubmed: 36831683
pii: cancers15041342
doi: 10.3390/cancers15041342
pmc: PMC9954183
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Clin Cancer Res. 2021 May 15;27(10):2723-2733
pubmed: 33622704
N Engl J Med. 2015 Jun 25;372(26):2481-98
pubmed: 26061751
Cancer Res. 2001 Apr 15;61(8):3225-9
pubmed: 11309270
J Biol Chem. 2011 Oct 14;286(41):35334-35338
pubmed: 21862836
Neuro Oncol. 2020 Aug 17;22(8):1226-1228
pubmed: 32215616
Neuro Oncol. 2019 Feb 14;21(2):189-200
pubmed: 30184215
Elife. 2015 Jul 21;4:
pubmed: 26194807
Asian J Neurosurg. 2019 Apr-Jun;14(2):356-363
pubmed: 31143247
Nat Med. 2015 Feb;21(2):178-84
pubmed: 25599133
Sci Adv. 2020 Apr 22;6(17):eaaz3221
pubmed: 32494639
Semin Cancer Biol. 2018 Aug;51:50-58
pubmed: 29170066
Continuum (Minneap Minn). 2015 Apr;21(2 Neuro-oncology):345-54
pubmed: 25837900
Int J Cancer. 2002 Oct 1;101(4):335-41
pubmed: 12209957
Int J Mol Sci. 2019 Jul 15;20(14):
pubmed: 31311166
Neuro Oncol. 2020 Nov 26;22(11):1580-1590
pubmed: 32166314
Neuro Oncol. 2021 Aug 2;23(8):1215-1217
pubmed: 34185090
Acta Neuropathol. 2015 Apr;129(4):597-607
pubmed: 25724300
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cancers (Basel). 2022 Feb 22;14(5):
pubmed: 35267433
Nat Genet. 2016 Jan;48(1):59-66
pubmed: 26618343
Science. 2013 May 17;340(6134):857-61
pubmed: 23539183
Clin Cancer Res. 2011 Jul 1;17(13):4588-99
pubmed: 21558404
Annu Rev Pharmacol Toxicol. 2005;45:629-56
pubmed: 15822191
Nat Commun. 2018 Aug 7;9(1):3142
pubmed: 30087349
Neurooncol Adv. 2020 Jan-Dec;2(1):vdaa025
pubmed: 32226942
Science. 2017 May 5;356(6337):
pubmed: 28473536
Acta Neuropathol. 2018 Apr;135(4):601-615
pubmed: 29368212
Cancer Res. 2007 Jan 1;67(1):194-201
pubmed: 17210699
Trends Genet. 2014 Oct;30(10):464-74
pubmed: 25132561
Genes Dev. 2011 May 15;25(10):1010-22
pubmed: 21576262
Acta Neuropathol. 2014 Oct;128(4):561-71
pubmed: 25008768
Lancet. 2012 May 26;379(9830):1984-96
pubmed: 22510398
Methods Mol Biol. 2012;863:139-53
pubmed: 22359291
Br J Pharmacol. 2015 Jun;172(11):2705-15
pubmed: 25134627
Nat Biotechnol. 2010 Oct;28(10):1057-68
pubmed: 20944598
Clin Exp Med. 2018 Feb;18(1):1-14
pubmed: 28752221
Acta Neuropathol. 2007 Aug;114(2):97-109
pubmed: 17618441
Acta Neuropathol. 2013 Aug;126(2):267-76
pubmed: 23764841
J Cell Mol Med. 2022 Jan;26(2):449-461
pubmed: 34894053
Acta Neuropathol. 2014 Feb;127(2):307-9
pubmed: 24337442
J Transl Med. 2019 Jun 24;17(1):210
pubmed: 31234870
Cancer Cell. 2017 Oct 9;32(4):520-537.e5
pubmed: 28966033
J Clin Invest. 2021 Feb 15;131(4):
pubmed: 33332283
Nature. 2021 Apr;592(7854):463-468
pubmed: 33762734
Pediatr Blood Cancer. 2018 Feb;65(2):
pubmed: 29090526
Org Biomol Chem. 2018 Feb 28;16(9):1419-1435
pubmed: 29265160
Nat Rev Clin Oncol. 2021 Mar;18(3):170-186
pubmed: 33293629
Neurology. 2010 Oct 26;75(17):1560-6
pubmed: 20975057
J Neurooncol. 2020 Oct;150(1):27-34
pubmed: 32804378
Nat Commun. 2017 Oct 20;8(1):1067
pubmed: 29057925
Brain Pathol. 2020 Jul;30(4):844-856
pubmed: 32307792
Cancer Cell. 2015 Dec 14;28(6):773-784
pubmed: 26678339
Science. 2013 May 3;340(6132):626-30
pubmed: 23558169
Nature. 2018 Mar 22;555(7697):469-474
pubmed: 29539639
Annu Rev Pathol. 2022 Jan 24;17:295-321
pubmed: 34736341
EMBO J. 2003 Dec 1;22(23):6335-45
pubmed: 14633992
Lancet Oncol. 2017 Jun;18(6):e315-e329
pubmed: 28483413
Genomics. 2020 Nov;112(6):4808-4816
pubmed: 32882327
Clin Cancer Res. 2021 Aug 15;27(16):4491-4499
pubmed: 34078652
Clin Cancer Res. 2019 Feb 15;25(4):1261-1271
pubmed: 30397180
Neuro Oncol. 2019 Jul 11;21(7):837-853
pubmed: 30753579
Bioessays. 1996 Nov;18(11):875-84
pubmed: 8939065
Front Oncol. 2022 Jan 17;11:629521
pubmed: 35111661
Cell. 2018 Sep 20;175(1):101-116.e25
pubmed: 30220459
Trends Genet. 2005 Nov;21(11):608-15
pubmed: 16153738
Neurology. 2014 Sep 23;83(13):1200-6
pubmed: 25150284
Br J Cancer. 2022 Nov;127(11):2006-2015
pubmed: 36175618
Nat Chem Biol. 2012 Feb 12;8(4):328-30
pubmed: 22327402
Acta Neuropathol. 2017 Jan;133(1):1-3
pubmed: 27909809
Nat Immunol. 2017 Sep;18(9):985-994
pubmed: 28714978
Cancer Cell. 2011 Jan 18;19(1):17-30
pubmed: 21251613
Neuro Oncol. 2022 Oct 5;24(Suppl 5):v1-v95
pubmed: 36196752
Mutat Res Rev Mutat Res. 2017 Jan - Mar;771:15-31
pubmed: 28342451
Indian J Pathol Microbiol. 2022 May;65(Supplement):S5-S13
pubmed: 35562129
Neuro Oncol. 2013 May;15(5):595-606
pubmed: 23393207
Biochem Pharmacol. 2006 Nov 30;72(11):1563-9
pubmed: 16836980
Cell Mol Life Sci. 2004 Oct;61(19-20):2571-87
pubmed: 15526163
Brain Tumor Res Treat. 2014 Apr;2(1):7-21
pubmed: 24926467
Neurooncol Pract. 2020 Aug 29;8(1):4-10
pubmed: 33664964
Nat Commun. 2019 Mar 19;10(1):1262
pubmed: 30890717
Sci Transl Med. 2017 Feb 1;9(375):
pubmed: 28148839
Genome Med. 2015 Jan 29;7(1):9
pubmed: 25632305
Nat Genet. 2015 May;47(5):458-68
pubmed: 25848751
Oncotarget. 2013 Oct;4(10):1729-36
pubmed: 24077826
Lancet Oncol. 2013 May;14(6):534-42
pubmed: 23598174
Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931
Clin Cancer Res. 2020 Apr 1;26(7):1690-1699
pubmed: 31900275
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Acta Neuropathol Commun. 2015 Jan 21;3:4
pubmed: 25849072
Ann Neurol. 2003 Apr;53(4):524-8
pubmed: 12666121
Oncologist. 2014 Apr;19(4):403-13
pubmed: 24664484
Nucleic Acids Res. 2001 Nov 15;29(22):4598-606
pubmed: 11713309
Front Oncol. 2017 Mar 28;7:45
pubmed: 28401060
Acta Neuropathol. 2020 Mar;139(3):603-608
pubmed: 31996992
J Neurooncol. 2012 May;107(3):617-31
pubmed: 22287028
ACS Med Chem Lett. 2018 Jan 19;9(4):300-305
pubmed: 29670690
Nat Commun. 2020 Dec 2;11(1):6161
pubmed: 33268789
Brain Tumor Pathol. 2022 Apr;39(2):47-50
pubmed: 35316415
J Clin Oncol. 2020 Oct 10;38(29):3398-3406
pubmed: 32530764
Neuro Oncol. 2023 Feb 14;25(2):326-336
pubmed: 35722822
Curr Neurol Neurosci Rep. 2017 Feb;17(2):19
pubmed: 28271343
Oncogene. 2010 Dec 9;29(49):6409-17
pubmed: 20972461
Nat Rev Genet. 2007 Apr;8(4):286-98
pubmed: 17339880
Cancer Res. 2002 Dec 15;62(24):7213-8
pubmed: 12499261
Brain Tumor Pathol. 2020 Apr;37(2):33-40
pubmed: 32227259
N Engl J Med. 2009 Feb 19;360(8):765-73
pubmed: 19228619
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Neurosurg Clin N Am. 2019 Jan;30(1):17-25
pubmed: 30470401
Cell. 1999 Aug 6;98(3):285-94
pubmed: 10458604
Mod Pathol. 2015 Feb;28(2):177-86
pubmed: 25081751
BMC Cancer. 2018 May 29;18(1):599
pubmed: 29843637
Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6021-6
pubmed: 23530248
Neuro Oncol. 2017 Oct 19;19(11):1460-1468
pubmed: 28531337
Sci Rep. 2017 Oct 23;7(1):13853
pubmed: 29062039
Annu Rev Biochem. 2005;74:481-514
pubmed: 15952895
Oncotarget. 2013 Oct;4(10):1737-47
pubmed: 24077805
Int J Mol Med. 2016 Jan;37(1):251-7
pubmed: 26718491
Acta Neuropathol. 2005 Jan;109(1):93-108
pubmed: 15685439
Adv Genet. 2010;70:27-56
pubmed: 20920744